GSK logo

GSKGlaxosmithkline plc - ADR

$52.98
$1.81
(3.54%)
Today
Updated: 01:46 PM EDT
EarningsJul 28
Mkt Cap$102.61B
Vol2.74M
67

Bullish Sentiment

How do you feel about GSK?

News
all
press releases
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
Zacks
News Placeholder
More News
News Placeholder
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00...
Business Wire
News Placeholder
Viral Influencer: How Bill Gates' Billions Shape US Medical Research
Viral Influencer: How Bill Gates' Billions Shape US Medical Research Authored by Paul D. Thacker via RealClearInvestigations, Bill Gates has long been one of the most admired people in the world, especially since he stepped down from his role running Microsoft to devote himself and...
Zero Hedge
News Placeholder
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Zacks
News Placeholder
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Zacks
News Placeholder
The $100 Billion Oncology Opportunity Investors are Starting to Notice
Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. $NTHI, $GSK, $NUVL, $PFE, $RHHBY, $BMY
24-7 Market News
News Placeholder
Futures Rise As Tech Rebound Extends While Oil Drops
Futures Rise As Tech Rebound Extends While Oil Drops US equity futures are higher as Monday's US stock gains extend into today's trading?with both tech and small caps outperforming as the AI theme resumes its global surge and US/Iran deal optimism is back (on the back of the now daily...
Zero Hedge
News Placeholder
Stocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more
These are the stocks posting the largest moves in early trading...
CNBC: Top News
News Placeholder
Market Digest: AEP, APA, CHD, GSK, HP, PRU, WBD
Market Digest: AEP, APA, CHD, GSK, HP, PRU, WBD...
Yahoo! Finance: News
News Placeholder
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.